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A successful HIV-1 vaccine will likely need to elicit broadly
neutralizing antibodies (bNAbs) that target the envelope glyco-
protein (Env) spike on the virus. Native-like recombinant Env
trimers of the SOSIP design now serve as a platform for achiev-
ing this challenging goal. However, SOSIP trimers usually do
not bind efficiently to the inferred germline precursors of
bNAbs (gl-bNAbs). We hypothesized that the inherent flexibili-
ties of the V1 and V2 variable loops in the Env trimer contribute
to the poor recognition of gl-bNAb epitopes at the trimer apex
that extensively involve V2 residues. To reduce local V2 flexibil-
ity and improve the binding of V2-dependent bNAbs and gl-
bNAbs, we designed BG505 SOSIP.664 trimer variants contain-
ing newly created disulfide bonds intended to stabilize the V2
loop in an optimally antigenic configuration. The first variant,
I184C/E190C, contained a new disulfide bond within the V2
loop, whereas the second variant, E153C/R178C, had a new
disulfide bond that cross-linked V2 and V1. The resulting engi-
neered native-like trimer variants were both more reactive with
and were neutralized by V2 bNAbs and gl-bNAbs, a finding that
may be valuable in the design of germline targeting and boosting
trimer immunogens to create an antigenic conformation opti-
mal for HIV vaccine development.
There remains an urgent need to create an effective vaccine
to reduce the further spread of HIV-1. Many vaccine design
strategies are now based on the elicitation of broadly neutraliz-
ing antibodies (bNAbs)2 that recognize the envelope glycopro-
tein spike (Env) on the surface of infectious viruses (1, 2).
Achieving this goal is a formidable challenge that requires
harnessing structure-based Env immunogen design and an
increased understanding of the immunology and genetics of
how bNAbs evolve in a subset of infected individuals (3, 4). A
now widely used immunogen development platform is based
on native-like, recombinant soluble trimers of the SOSIP design
(5, 6).
The native Env trimer is embedded in the HIV-1 membrane
and is composed of three gp41 subunits that are noncovalently
linked to three gp120 subunits (7, 8). Each gp120 subunit is
composed of five conserved domains (C1–C5) and five variable
domains (V1–V5) that are shielded by 25–35 N-linked glycans.
Three or four additional glycans are present on ectodomain of
gp41 (9). Nine highly conserved disulfide bonds help to main-
tain gp120 in an appropriate configuration, and another disul-
fide bond is present within the gp41 ectodomain (10, 11). The
gp120 disulfide bonds are mostly located in the core structure
from which the variable loops and N-linked glycans protrude (8,
12, 13). The stems of the V1, V2, V3, and V4 loops are all stabi-
lized by disulfide bonds. Some HIV-1 isolates contain addi-
tional cysteine residues within the V2 and/or V4 loops, allowing
the formation of a tenth and, in rare cases, an eleventh disulfide
within the gp120 subunit (14 –18). An additional intra-V2
disulfide is frequently present in HIV-2 and SIV gp120 proteins
(18). When gp120 monomers or nonnative gp140 proteins are
expressed as recombinant proteins, “scrambling” of some disul-
fide bonds, particularly in the V1V2 region, generally occurs,
leading to the production of misfolded proteins (19, 20). This
problem does not, however, apply to SOSIP trimers (21, 22).
Multiple bNAbs target an epitope cluster centered on the V2
domain at the trimer apex, including PG9, PG16, PGT145,
PGDM1400, CH01, PCT64, VRC38, and VRC26.09 (from
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hereon termed V2 bNAbs) (23–25). In general, the V2 bNAbs
recognize one or two of the glycans at positions 156 and 160,
together with a relatively conserved peptide sequence: the pos-
itively charged -strand C (residues 166 –176) (26 –35). Com-
ponents from two or three gp120 monomers are required to
fully form these epitopes. Hence the V2 bNAbs are either truly
quaternary in nature (trimer-specific) or trimer-preferring.
Their binding to -strand C is frequently mediated via an
unusually long CDRH3 loop that penetrates a small gap
between the glycans at positions 156 and 160 (26 –35). The V2
bNAbs are of interest for Env immunogen design because they
are elicited relatively frequently and rather sooner during
HIV-1 infection compared with other bNAb classes (36 –38).
Accordingly, their maturation has been found to require a com-
paratively low percentage of somatic hypermutation (27, 31,
39 – 41).
As noted above, the BG505 and other genotypes of the
SOSIP.664 native-like trimer now serve as platforms for struc-
ture-guided immunogen design as part of bNAb-development
programs (8, 12, 13, 42– 45). One fruitful avenue of exploration
is to improve how SOSIP trimers present specific bNAb
epitopes to naïve B cells by stabilizing them. The V2 bNAb
epitope cluster is particularly attractive from this perspective in
view of the exceptional flexibility of this region of the trimer (26,
46, 47), which might hinder a productive interaction with the
appropriate B-cell receptors (BCRs) on naïve B cells and thus
not lead to effective B cell activation and affinity maturation.
Rigidifying the V2, and also the nearby V1, might also reduce
the extent to which these loops shield other bNAb epitopes,
such as those associated with the CD4bs (48 –52). Thus, several
studies have linked the length of the V1 and V2 loops with the
neutralization sensitivity of viruses, longer loops with a con-
comitantly increased number of glycan sites being associated
with resistance (14, 49, 52–54).
The availability of high-resolution structural information on
the architecture of BG505 and other SOSIP trimers is a critical
guide to design improvements, including those to the V2 bNAb
epitopes. The V1V2 domain folds into a four stranded anti-
parallel -sheet Greek key motif in which strands A and B
are connected by the flexible V1 loop and strands C and D by
the flexible V2 loop (8, 12, 13, 26, 43). Interactions between the
V1V2 domains of different gp120 subunits help to stabilize
the trimer apex and thereby the entire trimer; additional inter-
actions with the V3 domain stabilize the prefusion conforma-
tion of the trimer, in which V3 domain is sequestered under-
neath the V1V2 loops (13, 43, 44, 55, 56). The overall flexibility
of the V1V2 domains on the prefusion trimer is indicated by the
lack of density for many residues and the high B-values for
others in this area of the trimer (8, 12, 13, 43– 45, 57, 58).
Hydrogen deuterium exchange analyses of SOSIP trimers pro-
vide additional information on comparatively unusual flexibil-
ity of the V1 and V2 loop regions (46, 47).
Here, we sought to stabilize the V1 and V2 domains by intro-
ducing disulfide bonds either within the V2 loop or between the
V1 and V2 loops. We show that both strategies can improve the
presentation of V2 bNAb epitopes. Thus, the resulting SOSIP
trimer variants have improved reactivity with V2 bNAbs and
their inferred germline (gl) precursors. Moreover, the corre-
sponding virus mutants are more sensitive to neutralization by
V2 bNAbs. These trimer-improvement methods may therefore
play a role in bNAb-induction strategies.
Results
Design of V2-internal and V1-V2 disulfide bonds at the trimer
apex
We designed disulfide bond mutants to stabilize the flexible
V1 and V2 domains on BG505 SOSIP.664 trimers (Fig. 1, A–C).
To stabilize both domains simultaneously, we constructed
three mutants, K155C/F176C, I154C/Y177C, and E153C/
R178C, in which the C-terminal part of V1 is now linked to the
N-terminal part of V2 by an engineered interloop disulfide
bond (Fig. 1C). This category of mutant is hereafter referred to
by the term V1-V2 disulfide bond. The positions for the Cys
substitutions were chosen because of the close proximity of
residues Lys155 and Phe176 (5.5 Å distance between the -car-
bons (C) atoms; PDB code 5CEZ), Ile154 and Tyr177 (5.4 Å),
and Glu153 and Arg178 (4.1 Å); at such distances, it seemed
feasible that a disulfide bond could be formed (44) (Fig. 1C).
We also elected to stabilize the V2 loop by creating a new
disulfide bond within it. Accordingly, we designed two mutants:
Q183C/E190C and I184C/E190C (Fig. 1, A–C). This category of
mutant is hereafter referred to by the term V2-internal disulfide
bond. The positions for the Cys substitutions were chosen
because a twin cysteine motif is present at the corresponding
positions in the V2 loops of SIV and HIV-2 Env and has been
suggested to lead to the formation of a loop-stabilizing disulfide
bond (Fig. 1D) (18). As for the V1-V2 disulfide bonds, we used
the SOSIP trimer structure to show that residues 184 and 190
are in close proximity (C distance of 5.7 Å), which favors disul-
fide bond formation, whereas residues 183 and 190 are slightly
farther apart (6.4 Å; Fig. 1C).
The five disulfide bond mutants described above were
introduced into a D7324-tagged BG505 SOSIP.664 construct
(Fig. 1, A–C), and the resulting proteins were expressed tran-
siently in 293T cells. We then assessed the yield, trimer for-
mation, and antigenicity of each mutant, using the unpuri-
fied culture supernatants. All three V1-V2 disulfide mutants
were expressed at acceptable yields (Fig. S1A), but a BN-
PAGE gel showed that trimer formation was severely
impaired (Fig. 1E). The implication is that the disulfide
bond–linked V1V2 domains are no longer able to form the
intersubunit interactions at trimer apex that are important
for trimer formation. The conformationally nonselective
2G12 and VRC01 bNAbs bound the various V1-V2 disulfide
bond mutant proteins efficiently (Fig. 1F and Fig. S1B).
However, the conformationally sensitive (trimer-specific or
trimer-preferring) bNAbs PG9, PG16, and PGT145 failed to
bind to the K155C/F176C and I154C/Y177C mutants and
reacted only poorly with the E153C/R178C mutant. These
data patterns are consistent with the poor formation of trim-
ers seen in the gel-based analysis (Fig. 1F and Fig. S1B).
The V2-internal disulfide bond mutants were both slightly
less efficiently expressed than the parental BG505 SOSIP.664
construct (Fig. S1A). The Q183C/E190C mutant failed to form
trimers, but a moderate level of trimer formation was observed
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Figure 1. Design and preliminary characterization of BG505 SOSIP.664 disulfide bond mutants. A, linear representation of BG505 SOSIP.664 and its V1-V2
and V2-internal disulfide bond mutants. The engineered disulfide bonds are indicated in blue. The glycan composition of the SOSIP.664 trimer is derived from
Ref. 9. B, crystal structure of the BG505 SOSIP.664 trimer (PDB code 5CEZ (44)). The protomers are colored as follows: gp41 subunit in cyan, V1 loop in purple, V2
loop in orange, and other gp120 domains in green. C, detailed view of the V1V2 region. Residues that are changed to a cysteine in the V1-V2 disulfide bond
mutants are shown as sticks. The distances (in Å) between the  carbons (C) of the mutated residue pairs are given next to the yellow dotted lines. D, alignment
of the V2 region (residues 168 –205) of several HIV-1, SIV and HIV-2 sequences (adapted from Ref. 18). Residues 184 and 190 (HxB2 numbering) are highlighted
in yellow to show the cysteine pair (i.e. presumed V2-internal disulfide bond) that is present in SIV and HIV-2 sequences but absent from HIV-1. E, the indicated
293T cell-expressed SOSIP.664 and disulfide mutant proteins were analyzed by BN-PAGE followed by Western blotting with bNAb 2G12. F, summary of bNAb
binding of the same SOSIP.664 proteins. The binding efficiency, based on the area under the curve (AUC) values, is indicated by the following code: , very
strong binding; , strong binding; , moderate binding; /, weak binding; , no binding.
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for the I184C/E190C mutant (Fig. 1E). In the antigenicity stud-
ies, the Q183C/E190C mutant bound 2G12 and VRC01 some-
what less well than the SOSIP.664 comparator and did not bind
PG9, PG16, and PGT145 at all (Fig. 1F and Fig. S1C). In con-
trast, the I184C/E190C mutant bound comparably to 2G12 and
VRC01 and was also reactive with PG9, PG16, and PGT145,
albeit to a lesser extent than SOSIP.664 (Fig. 1F and Fig. S1C).
We judged that the extent of binding of these three V2 bNAbs
was sufficient to pursue further studies of this V2-internal
disulfide bond mutant (see below).
Evolutionary rescue of the V1-V2 disulfide bond mutants in LAI
virus
Although the K155C/F176C, I154C/Y177C, and E153C/
R178C V1-V2 disulfide bond mutants formed trimers very inef-
ficiently, we decided to explore whether their defects could be
improved by using a virus evolution procedure. To do so, we
introduced each of the three cysteine pairs into a HIV-1 LAI
molecular clone, because this virus has been used successfully
to repair Env folding defects caused by changes in the V1V2
domain and/or the overall disulfide bond architecture (59 –62).
The LAI clone we used was engineered to introduce four amino
acids that create the PG9 epitope, as judged by neutralization
sensitivity (see “Materials and methods” for details).
As expected from the studies on the BG505 trimers, none of
the three V1-V2 disulfide bond mutant LAI viruses was infec-
tious, as measured in a single round infection assay in TZM-bl
cells (Fig. 2A). Each mutant virus was therefore passaged for a
prolonged period in two independent SupT1 T cell cultures to
see whether compensatory mutations arose that increased
replication efficiency. The K155C/F176C and I154C/Y177C
mutants failed to replicate detectably during the 3-month
experiment, indicating that their defects were beyond repair.
However, the E153C/K178C mutant acquired replication com-
petence in both cultures after 3 weeks (note that position 178 in
the LAI clone is a lysine and not the arginine present at the
corresponding position in BG505 Env). Proviral DNA was
therefore sequenced after 1, 2, and 3 months of culture. In both
cultures, a point substitution at position 152 was found to have
emerged within 1 month (Fig. 2B). Specifically, glycine 152 had
changed to either glutamic acid (G152E; culture 1) or valine
(G152V; culture 2). The significance of these observations is
that residue 152 is directly adjacent to the cysteine substitution
at position 153. The changes at position 152 persisted to the end
of the 3-month culture period, but we also found that a second
change, S128R, arose in the virus in culture 1 (Fig. 2B).
We next assessed the ability of the E153C/K178C virus qua-
sispecies from the SupT1 cultures to infect TZM-bl cells and
found that there was a gradual gain of infectivity during the 3
months of evolutionary rescue. By the end of the culture period,
the E153C/K178C mutant virus in SupT1 cultures 1 and 2
showed infectivity levels of 50 and 100% compared with the
parental LAI-PG9 virus, respectively (Fig. 2C). To confirm
that the G152E, G152V, and S128R compensatory mutations
identified by sequencing the env genes were in fact respon-
sible for the restored infectivity, we introduced these
changes individually or in combination into an LAI clone
that also contained the Cys153–Cys178 V1-V2 disulfide bond.
In all three cases, the resulting virus mutants and the qua-
sispecies present in the evolution cultures at month 3 had
comparable infectivities for TZM-bl cells (Fig. 2C). The sub-
Figure 2. Evolutionary repair of V1-V2 disulfide bond mutant LAI viruses. A, relative infection of TZM-bl cells by the indicated parental and disulfide bond
mutant LAI viruses, as measured by a luciferase assay. B, schematic timeline showing the mutations that were found over time in SupT1 evolution cultures 1 and
2 that were infected by the E153C/K178C V1-V2 disulfide mutant. C, infection of TZM-bl cells by the LAI-PG9 virus; the E153C/K178C mutant; supernatants from
the SupT1 evolution cultures taken after 1, 2, or 3 months; and the E153C/K178C virus variants containing the compensatory changes identified in the evolution
cultures (changes indicated in bold). Left panel, evolution culture 1; right panel, evolution culture 2. The mean infectivity of four individual measurements is
depicted in all graphs, in which individual measurements are shown as dots.
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stitutions at position 152 had the strongest effect, whereas
the S128R change modestly increased the infectivity of the
G152E mutant. Taken together, the evolutionary repair
experiments show that a compensatory substitution at posi-
tion 152, either G152E or G152V, partially restores the infec-
tivity of an otherwise replication-defective E153C/K178C
V1-V2 disulfide bond mutant LAI virus.
The G152E substitution improves trimer formation by the
BG505 SOSIP.664 E153C/R178C V1-V2 disulfide bond mutant
To assess whether the LAI compensatory mutations at resi-
due 152 would translate to the BG505 SOSIP.664 trimer con-
text, we introduced either the G152E or G152V change into the
SOSIP.664 E153C/R178C mutant and expressed the proteins
by transiently transfecting 293T cells. The G152E compensa-
tory mutation clearly improved both trimer formation, judged
using a BN-PAGE gel and the binding of the conformationally
sensitive V2 bNAbs (Fig. 3A and Fig. S2B). However, the G152V
mutation was not beneficial (Fig. 3A and Fig. S2B).
We then expressed the BG505 SOSIP.664 WT, E153C/
R178C, and E153C/R178C/G152E constructs in 293F cells,
purified the resulting Env proteins via 2G12 affinity chromatog-
raphy, and analyzed them with size-exclusion chromatography
(SEC). 2G12 binds to all possible forms of Env (aggregates, trim-
ers, dimers, and monomers), and SEC allowed us to determine
the trimer formation efficiency for each Env protein. Compared
with SOSIP.664, the SEC profile of the E153C/R178C mutant
contained many more monomers and dimers and proportion-
ately far fewer trimers, but trimer formation was clearly
increased when the G152E change was also present (Fig. 3B),
confirming the results of the HEK 293T transfection (Fig. 3A).
Purification and characterization of loop-stabilized BG505
SOSIP.664 trimers
The improvement described above was not sufficient to
allow the BG505 SOSIP.664 E153C/R178C/G152E trimers to
be purified by the 2G12/SEC method. However, PGT145-affin-
ity chromatography is an alternative approach to isolate native-
like trimers (47, 63). We therefore used this method to purify
trimers from the SOSIP.664 E153C/R178C ( G152E) con-
structs and also the I184C/E190C V2-internal disulfide mutant.
In each case, trimers were successfully isolated, but at markedly
variable yields (Fig. 3C). Whereas the trimer yield for the BG505
SOSIP.664 construct was 2.0 mg/liter, the corresponding val-
ues for the E153C/R178C and E153C/R178C/G152E variants
were 0.2 and 0.6 mg/liter, respectively (Table 1). The yield
of I184C/E190C V2-internal disulfide bond mutant trimers was
0.8 mg/liter (Table 1). As expected, all of the PGT145-puri-
fied trimer variants were cleaved, judged using reducing and
nonreducing SDS-PAGE gels (Fig. 3D).
To confirm that the engineered disulfide bonds had actually
formed, the loop-stabilized BG505 SOSIP.664 trimers were
trypsin-digested into fragments that were analyzed by MS to
identify peptides linked by disulfide bonds (21). The E153C/
R178C V1-V2 and I184C/E190C V2-internal disulfide bonds
were successfully identified among the respective trimer-de-
rived peptides (Fig. S3A). Alternative (i.e. aberrantly formed)
disulfide bonds were also detected in low abundance, but they
were quantitatively and qualitatively similar to ones previously
identified in the WT BG505 SOSIP.664 trimer (21). We con-
clude that in the PGT145-purified disulfide mutant trimers, the
engineered cysteine residues do form the intended V1-V2 or
V2-internal disulfide bonds, without appreciable aberrant
disulfide bonds (Fig. S3B).
Negative-stain (NS) EM showed that the PGT145-purified
SOSIP.664 E153C/R178C, E153C/R178C/G152E, and I184C/
E190C disulfide bond mutant trimers were all in a native-like
conformation. The SOSIP.664 trimer was in a closed, fully
native-like conformation (95%), as reported previously (Fig.
3E) (42). In contrast, the E153C/R178C V1-V2 disulfide bond
mutant trimers, although still native-like, contained a major
subpopulation (64%) that was partially open and a minor sub-
population (13%) that was fully open in an overall conformation
that resembled the CD4-bound state (Table 1 and Fig. 3E)
(64). The presence of additional density outside the trimer
core resembles loop flexibility and is described to represent a
partially open trimer conformation (22, 63). We have not
previously seen the fully open conformation when various
SOSIP trimers are PGT145-purified (47, 63). The implica-
tion is that the V1-V2 disulfide mutant is unstable and/or has
a high tendency to sample more open conformations. How-
ever, the E153C/R178C/G152E mutant was mostly (68%) in
the closed native-like conformation, reflecting the beneficial
effect of the G152E change (Table 1 and Fig. 3E). The I184C/
E190C V2-internal disulfide bond mutant had a very similar
appearance to the SOSIP.664 parental trimer, being predom-
inantly (86%) in the closed native-like conformation (Table 1
and Fig. 3E).
We used differential scanning calorimetry (DSC) to quantify
the thermostability of the modified SOSIP.664 trimers. The
E153C/R178C V1-V2 disulfide bond mutant was slightly less
thermostable than SOSIP.664 (Tm  65.3 °C versus 66.6 °C),
whereas the additional presence of the G152E compensatory
mutation reverted the Tm to 66.7 °C (Table 1 and Fig. 3F). The
corresponding Tm value of 66.3 °C for the I184C/E190C V2-in-
ternal disulfide bond mutant trimer was also almost identical to
SOSIP.664 (Table 1 and Fig. 3G). Thus, in contrast to when
disulfide bonds are introduced into the core regions of a gp120
monomer (I201C/A433C) (58) or SOSIP trimer (E49C/L555C
and A73C/A561C) (44, 65), engineering disulfide bonds into
the V1V2 region of the SOSIP.664 trimer does not increase
thermostability. The implication is that thermostability as mea-
sured by DSC is predominantly determined by the Env protein
core and not by the external loops. In summary, via structure-
guided design, virus evolution, and PGT145 positive selection
methodologies, we were able to purify native-like BG505
SOSIP.664 trimers with an additional disulfide bond either
within the V2 loop or linking the V1 and V2 loops.
Improved binding of V1-V2 and V2-internal disulfide bond
mutant trimers to V2 bNAbs and gl-bNAbs
The goal of our studies was to investigate whether we could
improve the antigenicity of SOSIP.664 trimers for V2 bNAbs.
We therefore tested an extensive panel of bNAbs and non-
NAbs for their abilities to bind the disulfide mutant trimers in
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Figure 3. Biochemical analysis of BG505 SOSIP.664 disulfide mutants. A, BN-PAGE and Western blotting analysis of culture supernatants from 293T cells
expressing the SOSIP.664 or V1-V2 disulfide mutant proteins. B, SEC chromatogram of the indicated SOSIP.664 and V1-V2 disulfide mutant proteins, isolated by
2G12 affinity chromatography from 293T cell culture supernatants. C, Coomassie Blue–stained BN-PAGE gel of the PGT145-purified SOSIP.664 and disulfide
mutant proteins. D, Coomassie Blue–stained reducing ( DTT) or nonreducing ( DTT) SDS-PAGE gels of the same PGT145-purified trimers. E, 2D class averages
of NS-EM analysis of the indicated PGT145-purified disulfide mutant trimers. NS-EM analysis of 2G12–SEC-purified BG505 SOSIP.664 was used as control, which
shows a similar closed native-like trimer conformation as previously described (47, 65). The percentages of closed native-like, partially open native-like, and
fully open trimers (64) are shown in green, green, and red, respectively (Table 1). The red arrows indicate fully open E153C/R178C V1-V2 disulfide mutant trimers
that resemble the CD4-bound conformation of the SOSIP.664 trimer (CD4 was not present in this experiment). F, thermal melting profiles for the indicated
PGT145-purified SOSIP.664 or V1-V2 disulfide mutant proteins obtained by DSC. G, DSC profile for the I184C/E190C V2-internal disulfide mutant.
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an ELISA. The various trimers were purified by PGT145 affinity
chromatography as described above.
Compared with BG505 SOSIP.664, the E153C/R178C V1-V2
disulfide mutant bound the VRC01, PGT151, and 2G12 slightly
less well, whereas the 19b, 14e, and 17b non-NAbs targeting V3
and CD4i epitopes bound more strongly (Fig. 4A). Taken
together, these results imply that the more open appearance of
these trimers observed in NS-EM studies is associated with an
antigenically less preferred conformation. The introduction of
the G152E compensatory mutation improved VRC01, PGT151,
and 2G12 binding and was also extremely beneficial to the
epitopes for the V3-glycan bNAb PGT121 and the V2 bNAbs
PG9, PG16, and CH01; indeed, the latter four bNAbs bound
better to the E153C/R178C/G152E mutant than to SOSIP.664
(Table 2 and Fig. 4, A and B). An increased binding to CD4bs
bNAb CH103 was also observed for the E153C/R178C/G152E
mutant (Table 2 and Fig. 4B). However, several non-NAbs also
bound more strongly to this mutant trimer, compared with
SOSIP.664 (Table 2 and Fig. 4, A and B).
The I184C/E190C V2-internal disulfide bond mutant trimer
bound all the V2 bNAbs (PG9, PG16, PGT145, VRC26.09, and
CH01) better than SOSIP.664. The titration curves showed that
the maximum binding levels were substantially higher for the
mutant trimers compared with SOSIP.664 (Table 2 and Fig.
4B). Although binding to VRC01 was similar between mutant
and SOSIP.664 trimer, binding to CH103 was improved for the
V2-internal disulfide bond mutant trimer (Table 2 and Fig. 4B).
There were no, or only very minor, differences in how the 2G12,
PGT121, and PGT151 bNAbs or the F105 and 17b non-NAbs
bound to the mutant and parental SOSIP.664 trimers (Table 2
and Fig. 4B).
We also assessed whether the gl-PG9, gl-PG16, and gl-CH01
V2 bNAbs were more reactive with the mutant trimers. As
reported previously, all three gl-bNAbs bound detectably to the
BG505 SOSIP.664 trimer, albeit with lower affinities than
the corresponding mature bNAbs (Fig. 4B) (66). However, the
three gl-bNAbs each bound substantially more efficiently with
the I184C/E190C V2-internal disulfide mutant trimer than
with SOSIP.664 (Table 2 and Fig. 4B). Based on half-maximal
binding (EC50) values, gl-PG9 binding to the mutant was
increased by 5-fold, and the maximum binding level was also
higher (Fig. 4C). A similar pattern was seen for the gl-PG16 and
gl-CH01 bNAbs, although EC50 values could not be reliably
determined because the titration curves did not reach a plateau
(Table 2 and Fig. 4, B and C).
The V1-V2 disulfide bond mutant trimer was slightly more
reactive with gl-PG9, gl-PG16, and gl-CH01 compared with
SOSIP.664, although the beneficial effects of this engineered
disulfide were markedly less than those conferred by the V2-in-
ternal disulfide (Table 2 and Fig. 4B). None of the trimer vari-
ants bound gl-PGT145 or gl-VRC26.09 detectably (Table 2 and
Fig. 4C).
Binding of V2 bNAbs to the V1-V2 disulfide mutant and
SOSIP.664 trimer was not affected by preincubation of up to 10
days at 37 °C, indicating the exceptional robustness of the disul-
fide mutant BG505 trimers (Fig. S4). The binding site for
gl-PG9 also remained stable over time on the V1-V2 disulfide
mutant trimers, although incubation at 37 °C reduced the bind-
ing strength by 40% (Fig. S4).
To study the Ab–antigen interaction in a context that better
resembles the process of a B-cell receptor encountering an anti-
gen, we also analyzed the antigenicity of the trimers by biolayer
interferometry. Here, bNAbs are coated to the protein A sensor
followed by incubation of soluble purified BG505 trimers. In
line with the results in ELISA, binding of V2 bNAbs PGT145,
CH01, and PG16 to V1-V2 disulfide mutant trimers was
enhanced compared with binding to SOSIP.664 (Fig. 5). The
V2-internal disulfide bond mutant trimer showed the largest
increase in V2 bNAb binding while showing a minor increase in
binding to V3 non-NAbs 19b and 39F (Fig. 5).
Improved neutralization of V1-V2 and V2-internal disulfide
bond virus mutants by V2 bNAbs
To determine whether the engineered disulfide bonds
increased the presentation of V2 bNAb and gl-bNAb
epitopes on the native, virion-associated trimer, we made
variants of the BG505.T332N Env-pseudotyped virus con-
taining the E153C/R178C/G152E or I184C/E190C changes.
The V2-internal disulfide mutant virus was more sensitive to
neutralization by V2 bNAbs compared with BG505 (by
5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for
PGDM1400, and 6-fold for gl-PG16), although there was no
difference in the sensitivity of the two viruses to PGT145 and
VRC26.09, and gl-PG9 neutralized neither virus (Fig. S5 and
Table 3). For the V1-V2 disulfide mutant virus, the only dif-
ference compared with the WT virus was observed with
gl-PG16, which was 3-fold more potent (Fig. S5 and Table 3).
Neutralization sensitivity to antibodies 2G12 and PGT151
was similar between BG505.T332N and disulfide mutant
viruses, indicating that the overall NAb sensitivity was not
affected (Fig. S5). The data pattern implies that the V2 bNAb
and gl-bNAb epitopes are not stabilized in the same way by
the two disulfide mutational strategies tested here. Superpo-
sition of the Env trimer structure with a V1V2 scaffold
Table 1
Biochemical characterization of BG505 SOSIP.664 disulfide mutant trimers
The biophysical properties of 293F cell-expressed, PGT145-purified SOSIP.664-D7324 trimers were assessed using NS-EM to determine native-like trimer formation and
by DSC to quantify thermostability (Tm). The unprocessed EM data are shown in Fig. 3E. The DSC data were fitted using a two-state model (Fig. 3, F and G).
Construct (BG505 SOSIP.664) Yield
NS-EM DSC
Native-like trimers Closed Partially open Open Tm Tm
mg/liter % °C °C
Wildtype 2.0 95 95 5 0 66.6
E153C/R178C 0.2 95 20 65 15 65.3 1.3
E153C/R178C/G152E 0.6 95 70 30 0 66.7 0.1
I184C/E190C 0.8 95 85 15 0 66.3 0.3
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bound by PG9 shows that the V2 loop can interfere with V2
bNAb binding (Fig. 6A). Whether the V1-V2 disulfide bond
mutant improves binding of V2 bNAbs to the BG505 Env
trimer obviously depends on the position of the stabilized V2
loop and might be different for the V1-V2 disulfide and
V2-internal disulfide mutant trimers.
We noted that both disulfide bond mutant viruses were 10-
fold more sensitive to neutralization by CH103, whereas there
was no difference in sensitivity to VRC01, which also recognizes
a CD4bs epitope (Fig. S5). Whether the V2 loop interferes with
how different bNAbs see their CD4bs epitopes is likely to be
influenced by their angle of approach to the trimer. Because
CH103 approaches at a 45° angle relative to the trimer axis, it
comes into close proximity with the V2 region; hence any alter-
ation in the orientation of V2 caused by an engineered disulfide
could alter access of CH103 to its epitope (Fig. 6B). In contrast,
VRC01 approaches the CD4bs at an angle parallel to the virus
membrane and at 90° to the trimer axis, which means that its
neutralization potency is less likely to be affected by the precise
orientation of the V2 loop (Fig. 6B).
Figure 4. Antigenicity of BG505 SOSIP.664 disulfide mutants. The panels show the binding of the indicated bNAbs and non-NAbs to various PGT145-
purified trimers in a D7324-capture ELISA. A and B, bNAb and non-NAb binding to SOSIP.664 (red), the E153C/R178C V1-V2 mutant (light blue), the E153C/
R178C/G152E V1-V2 mutant (dark blue), and the I184C/E190C V2-internal disulfide mutant (green). C, the same proteins as in B, but with the indicated V2
gl-bNAbs tested in a modified version of the capture ELISA that was optimized for measuring gl-bNAb binding (see “Materials and methods”). The binding
curves in this figure are representative of three individual experiments. The mean AUC value was used to calculate fold changes when comparing Ab binding
to disulfide mutant trimers versus SOSIP.664. These values are listed in Table 2.
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Overall, the virus neutralization data and SOSIP.664 trimer-
binding data were generally concordant. Compared with their
unmodified counterparts, the V1-V2 and V2-internal disulfide
bond mutant trimers generally interact more strongly with V2
bNAbs and gl-bNAbs compared with SOSIP.664 trimers, and
this is also true for neutralization of the corresponding Env-
pseudotyped viruses. Thus, increases in Ab binding to the
V2-internal disulfide bond mutant trimer and neutralization of
the corresponding mutant virus by the same Ab were correlated
(r  0.64, p  0.037; Fig. 6C). However, there were also exam-
ples, such as gl-PG9, where stronger trimer binding did not
translate into more potent neutralization. The correlation was
not statistically significant for the V1-V2 disulfide bond mutant
trimer and virus (r  0.51, p  0.20; Fig. 6D). Thus, stabilization
of the V2 domain either by a disulfide bond within the V2 loop
or by one that links the V1 and V2 domains can improve the
presentation of V2 bNAb and/or gl-bNAb epitopes at the
trimer apex. However, the beneficial effects of the engineered
disulfide bond(s) are not universal for all the V2-targeted anti-
bodies, and the two strategies do not lead to identical outcomes.
Discussion
SOSIP trimers have become a widely used platform for struc-
ture-guided immunogen design strategies that aim to elicit
bNAbs in any of various possible ways. Here, we sought to
improve their presentation of bNAb and/or gl-bNAb epitopes,
in particular those located at the trimer apex, by reducing local
conformational flexibility. To do so, we designed and charac-
terized V1-V2 and V2-internal disulfide mutants of the BG505
SOSIP.664 trimer that were intended to stabilize the V2 loop
and its associated bNAb epitopes. Three steps were required to
create the desired disulfide mutant trimers: structure-based
design, virus evolution, and positive selection. We initially
designed five mutants with appropriately positioned cysteine
pairs (i.e. at residues that were close enough to allow formation
of a disulfide bond), but only two of them (E153C/R178C and
I184C/E190C) yielded trimers with reasonable efficiency. Even
for these mutants, there was a marked reduction in trimer yield
compared with the SOSIP.664 trimer. We assume that the
introduced cysteine residues interfere with the intricate pro-
cess of gp120 folding and trimer assembly, perhaps by forming
aberrant disulfide bonds leading to dead-end folding pathways
or by distorting the gp120 subunit enough to impede trimer
formation (11, 19 –21, 59, 67).
The E153C/R178C V1-V2 disulfide bond mutant formed
trimers particularly poorly, and when trimers did form, they
frequently sampled unusually open configurations that resem-
bled the CD4-bound conformation of the SOSIP.664 trimer.
Any adverse effects of the introduced cysteine residues may be
exacerbated when they are in different domains. We therefore
implemented a second procedure, virus evolution, to see
whether some of these defects could be overcome.
We have previously shown that virus evolution is an effective
technique for repairing folding problems associated with mod-
ifications in the V1V2 domain and/or changes in the disulfide
bond architecture of Env proteins (59 –62). Here, we used this
method to drive the evolution of compensatory mutations that
improved the stability, yield, and antigenicity of a replication
impaired E153C/K178C V1-V2 disulfide mutant LAI virus. The
most substantive improvement to virus replication was con-
ferred by the G152E change that is positioned directly adjacent
to the V1-component of the interdomain disulfide bond. We do
not yet know how the G152E compensatory mutation acts, but
it may increase the propensity of the adjacent cysteine 153 res-
idue to pair successfully with its V2 counterpart, cysteine 178.
Alternatively, it may stabilize the conformation of the V1V2
domain once the interloop disulfide bond is formed. When the
G152E substitution was made in the E153C/R178C V1-V2
disulfide bond mutant SOSIP.664 trimer, its conformational
stability was improved, and its propensity to adopt the unusu-
ally open conformation was reduced. Hence, what was learned
from the virus evolution method was translatable to the context
of the SOSIP.664 trimer.
An additional change that also emerged in the evolution cul-
ture, S128R, conferred a modest additional improvement to
infectivity. We note that a change at residue 128 (S128N) arose
in an evolutionary rescue culture of an HxB2 virus clone that
was crippled by the deletion of a key glycan at position 262. In
that case, the S128N change compensated for a substantial fold-
ing defect in the gp120 subunit (68 –70). We have not further
explored how the S128R change affects the SOSIP.664 trimer.
The third step that was required to isolate native-like disul-
fide mutant trimers was affinity purification using the trimer-
specific PGT145 bNAb. This positive-selection procedure
allowed the isolation of stable, native-like V1-V2 and V2-inter-
nal disulfide mutant trimers. Nevertheless, the eventual yields
of the V1-V2 and V2-internal disulfide trimers described here
were still substantially (4- and 3-fold, respectively) lower than
that of the parental BG505 SOSIP.664 trimer. If these mutant
trimers prove to be useful components of a bNAb-induction
strategy, additional steps will need to be taken to address this
limitation. For example, we have found that expressing a
mutant trimer in a stable CHO cell line can sometimes improve
TABLE 2
Antigenicity of BG505 SOSIP.664 disulfide mutant trimers
The binding of bNAbs, gl-bNAbs, and non-NAbs to PGT145-purified SOSIP.664
and mutant trimers was assessed by D7324-capture ELISA (Fig. 4). The AUC values
are measures of binding efficiency. The fold changes in AUC value compared to
SOSIP.664 for both mutants are listed, with those 1.5 highlighted in green.
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the yield by severalfold, and modifying key residues at the
gp120-gp41 interface can also be beneficial.
The V2-internal disulfide bond did improve the trimer bind-
ing of V2 bNAbs. One explanation may be that the flexible V2
loop assumes a conformation in which V2 bNAb epitopes are
transiently or permanently occluded on a subpopulation of
BG505 SOSIP.664 trimers. Such masking could be mediated by
the protein or the glycan components of the V2 loop itself or of
the nearby V1 loop. Whatever the explanation, several V2 and
one CD4bs bNAb epitopes were better presented on the V2-in-
ternal disulfide mutant trimer, perhaps because the additional
cross-link stabilizes the loop and reduces its propensity to
adopt a conformation in which certain epitopes are at least
partially occluded. The disulfide bond connecting the V1 and
V2 loops also improved the presentation of V2 bNAb epitopes,
although less so than the V2-internal disulfide. We also intend
to determine whether the V2-internal and V1-V2 disulfides can
be incorporated into SOSIP trimers of other genotypes. The
length of the V2 loop may be a variable that affects, in particu-
lar, the stabilizing and/or other effects of the V2-internal disul-
fide. Indeed, removal of 7 amino acids from the BG505 V2 con-
tributed to the engagement of V2 gl-bNAbs (71).
For an HIV-1 Env immunogen to induce bNAbs, it is likely to
be necessary that it can first activate naïve B-cells that express
appropriate gl-bNAb epitopes as their BCRs. A complex evo-
lutionary process may then drive the emergence of a true
bNAb. In this context, we found that the affinity of three
inferred V2 gl-bNAb precursors for the V2-internal disulfide
mutant was increased compared with SOSIP.664. Such an
affinity increase may enhance the probability that naïve
B-cells expressing similar gl-NAb epitopes will be found and
activated when the modified trimers are used as immuno-
gens. Whether improved antigenicity of the V2-internal
disulfide mutant trimer correlates with an improved immu-
nogenicity has to be addressed in future immunization stud-
ies. Such studies remain to be initiated, for example using
Figure 5. Antigenicity of BG505 SOSIP.664 disulfide mutants. Biolayer interferometry sensorgrams show that the binding of the indicated bNAbs and
non-NAbs to various PGT145-purified trimers (80 nM). The dotted lines indicate the end of the association phase (duration, 300 s) and the start of the dissociation
phase (duration, 300 s). The experiments were performed twice independently, and one representative experiment is shown.
Table 3
Neutralization sensitivity of BG505.T332N virus disulfide mutants
Neutralization sensitivity of the BG505.T332N Env-pseudotyped virus and disulfide
mutant stabilized variants. The IC50 values for the listed bNAbs and gl-bNAbs were
calculated from the neutralization curves for BG505.T332N (Fig. S5). The corre-
sponding values for the mutant viruses are presented as fold increases compared to
BG505.T332N. An increase in neutralization sensitivity (1.5 fold) is highlighted in
green. ND, not determined.
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knockin mice that express V2 gl-bNAbs as BCRs (72, 73).
The disulfide stabilization approach described here might be
complementary to other approaches aimed at improving
recognition by V2-apex gl-bNAbs (71, 74).
A V2-internal disulfide mutant (Cys183–Cys191) of the clade
C ZM109F Env-pseudotyped virus has recently been described
(75). The location of that disulfide is similar to the one we
describe here, i.e. I184C/E190C. In the context of the ZM109F
virus, the disulfide improved neutralization by Abs that bind
the integrin 47-binding LD(V/I) motif in V2. However, in
contrast to the effect of the disulfide that we introduced into the
BG505.T332N virus, the ZM109F mutant virus was not more
sensitive to neutralization by bNAb PG9 (75). The effect of a
V2-internal disulfide may therefore be genotype-dependent.
From an evolutionary perspective, it might be interesting to
determine what selective pressure was driving the evolutionary
loss of this twin cysteine motif in HIV-1 and when. After evolv-
ing in several SIV lineages, the twin cysteine motif disappeared
from most, but not all SIVcpz isolates and was then lost com-
pletely in HIV-1 (18). The presence of this motif, which
restrains the flexibility of the V2 loop, might have favored the
induction of V2 NAbs that exerted selection pressure. Indeed
several V1V2 targeting SIV NAbs have been isolated, providing
evidence for the presence of such a selective pressure on the
V1V2 loop structure (76). Thus, we can speculate that the evo-
lution from SIV to HIV might have involved enhancing the
flexibility of the V1 and V2 loops to prevent productive inter-
actions with naïve B-cells with the capacity to evolve into
V2-targeting (b)NAbs.
In conclusion, we designed and characterized V2-internal
and V1-V2 disulfide mutants to stabilize the V1 and/or V2 vari-
able loops on the BG505 SOSIP.664 trimer. The presentation of
several V2 and in some cases also CD4bs (gl-)bNAb epitopes
was improved when the V1 and V2 loops were stabilized by the
V1-V2 disulfide and more so by the V2-internal disulfide.
Materials and methods
Construct design
The BG505 SOSIP.664 construct has been described else-
where (42). It was generated by introducing the following
sequence changes: A501C and T605C (gp120-gp41ECTO
disulfide bond) (77); I559P in gp41ECTO (trimer-stabilizing)
(78); REKR to RRRRRR in gp120 (cleavage enhancement) (79);
Figure 6. Stabilizing the flexible V2 loop improves recognition of the BG505 Env trimer by the V2-apex bNAbs and some CD4bs bNAbs. A, superpo-
sition of the crystal structure of the BG505 SOSIP.664 trimer (green; PDB code 5CEZ) and the PG9 antibody (blue; PDB code 3U4E) in complex with a scaffolded
V1V2 domain (26, 44). The nine amino acids (ENQGNRSNN) in the V2 loop for which density is lacking in the trimer crystal structure are depicted as an orange
dotted line. B, a similar superposition of the same trimer structure and the VRC01 in complex with gp120 (purple; PDB code 3NGB) and CH103 (cyan; PDB code
4JAN) in complex with gp120 (81, 86). As in A, an orange dotted line depicts the residues in the V2 loop that lack density in the crystal structure. C and D,
correlation plots between bNAb binding efficiency (fold change in AUC compared with BG505 SOSIP.664 trimer) and bNAb neutralization capacity (fold
change in IC50 compared with BG505.T332N virus. C, I184C/E190C V2-internal disulfide mutant. D, E153C/R178C/G152E V1-V2 disulfide mutant. The r and p
values for nonparametric Spearman correlations are shown in the boxes.
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and a stop codon at gp41ECTO residue 664 (improvement of
homogeneity and solubility) (80). SOSIP.664-D7324 trimers
contain a D7324 epitope-tag sequence at the C terminus of
gp41ECTO and were constructed by adding the amino acid
sequence GSAPTKAKRRVVQREKR after residue 664 in
gp41ECTO (42). Point mutants were generated by QuikChange
site-directed mutagenesis (Agilent, Stratagene) and verified by
sequencing. All experiments described in this manuscript used
D7324-tagged trimers.
Env protein expression
The various SOSIP Env constructs were expressed by poly-
ethyleneimine-mediated transient transfection (together with
the furin gene) of adherent HEK 293T cells or of HEK 293F cells
adapted for serum-free suspension cultures, as previously
described (42, 47). For small-scale trimer expression, 293T cells
were used, and for larger-scale trimer production, 293F cells
were used. All experiments were performed with purified trim-
ers utilized 293F cell-expressed proteins.
Trimer purification
For screening purposes, unpurified 293T-expressed trimers
were analyzed directly using the culture supernatants obtained
6 days post-transfection. For extensive analysis of V2 bNAb
reactivity, Env trimers were purified from 293F transfection
supernatants by affinity chromatography using a PGT145 col-
umn or a 2G12 column followed by SEC, as described (42, 47,
63).ProteinconcentrationsweredeterminedusingUV280absor-
bance, and theoretical extinction coefficients were obtained via
the ExPASy webserver (ProtParam tool). Except for the exper-
iments described in Fig. 3B, which included 2G12-purified
trimers, all other experiments were performed with PGT145-
purified trimers.
SDS-PAGE and BN-PAGE
Env proteins were analyzed using SDS-PAGE and BN-PAGE,
followed by Western blotting or Coomassie Blue dye staining as
previously described (47, 78).
D7324-capture ELISA
The method to perform sandwich ELISAs using D7324-
tagged BG505 SOSIP.664 trimers has been described in detail
elsewhere (42, 82). In summary, trimers were immobilized at
1.0 g/ml via their D7324 tags for 2 h at room temperature on
half-well 96-well plates (Greiner) precoated with Ab D7324
(Aalto Bioreagents) at 10 g/ml in 0.1 M NaHCO3 (pH 8.6)
overnight. Serially diluted Abs were added for 2 h, washed, and
then detected using horseradish peroxidase–labeled goat anti-
human immunoglobulin (Jackson Immunoresearch). We also
used a modified D7324-capture ELISA protocol that was opti-
mized for detecting gl-bNAb binding (66). The modifications
compared with the regular protocol are as follows. Purified
BG505 SOSIP.664-D7324 trimers were added at 5 g/ml
instead of 2 g/ml, and casein-blocking buffer (Thermo Scien-
tific) was used as blocking agent instead of 2% milk in TBS.
Lectin ELISA
Purified BG505 trimers were incubated in PBS at room tem-
perature or at 37 °C for 0, 60, 120, 180, or 240 h, and subse-
quently antigenicity was assessed with a lectin ELISA. Greiner
half-well ELISA plates were coated with Galanthus nivalis lec-
tin (Vector Laboratories), followed by blocking of the plates
with casein blocking buffer. Then purified trimers were trans-
ferred to the plates in a concentration of 2.5 g/ml and incu-
bated at room temperature for 2 h. Next, binding of several
antibodies to the BG505 trimers was tested using the following
Ab concentrations: 2G12, 0.75 g/ml; PGT145, 0.75 g/ml;
glPG9, 5.0 g/ml; glPG16, 5.0 g/ml; glCH01, 5.0 g/ml; PG9,
0.75 g/ml; PG16, 0.75 g/ml; and CH01, 0.75 g/ml. After
incubating the antibodies for 1 h, similar steps were followed as
for the D7324 ELISA to detect antibody binding.
Biolayer interferometry
Antibody binding to purified BG505 trimers was studied
using a ForteBio Octet K2. All assays were performed at 30 °C
and with agitation set at 1000 rpm. Trimer and antibody dilu-
tions were made in running buffer (PBS, 0.1% BSA, 0.02%
Tween 20) in a final volume of 200 l/well. Antibody was
loaded on protein A sensors (ForteBio) at 1.0 g/ml in running
buffer until a binding threshold of 0.5 nm was reached. Trimers
were diluted in running buffer at 80 nM, and association and
dissociation were measured for 300 s. Trimer binding to a pro-
tein A sensor not loaded by antibody was set as background.
Negative-stain electron microscopy (EM)
PGT145-purified BG505 trimers were analyzed by negative
stain EM as previously described (47, 63, 83).
Differential scanning calorimetry
Thermal denaturation of purified Env proteins was studied
using a MicroCal VP-Capillary DSC calorimeter (Malvern
Instruments) or a nano-DSC calorimeter (TA Instruments) as
described previously (47). All Env protein samples were first
extensively dialyzed against PBS, and the protein concentration
was then adjusted to 0.1– 0.3 mg/ml. After loading the sample
into the cell, thermal denaturation was probed at a scan rate of
60 °C/h. Buffer correction, normalization, and baseline sub-
traction procedures were applied before the data were analyzed
using NanoAnalyze software version 3.3.0 (TA Instruments) or
Origin 7.0 software. The data were fitted using a two-state
model.
Disulfide bond analysis of BG505 trimers
The disulfide bond patterns of SOSIP.664 trimer variants
were determined as described previously (19, 20). In brief, sam-
ples containing 20 g of trimer were alkylated with a 10-fold
molar excess of 4-vinylpyridine for 1 h at room temperature in
the dark, to cap free cysteine residues. Deglycosylation was per-
formed by incubating trimers with 1 l of peptide:N-glycosi-
dase F solution (500,000 units/ml) in 100 mM ammonium cit-
rate buffer (pH 6.5) for 1 week at 37 °C. The fully deglycosylated,
and alkylated samples were digested overnight with trypsin
(protein to enzyme ratio of 30:1) at 37 °C and were then ana-
lyzed by LC-MS using an Orbitrap Velos ProTM hybrid
(Thermo Scientific, San Jose, CA) mass spectrometer equipped
with electron transfer dissociation module and coupled to an
Acquity ultra performance liquid chromatography system
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(Waters, Milford, MA). Approximately 5 l (1 g equivalent) of
the tryptic digest was injected onto a C18 PepMapTM 300 col-
umn (300-m inner diameter  15 cm, 300 Å; Thermo Scien-
tific, Sunnyvale, CA), and the peptides were separated using a
linear gradient starting from 3% B to 40% B gradient in 50 min
and then 90% B for 10 min followed by re-equilibration at 97% A
for 10 min. LC-MS runs were performed with a flow rate of 5
l/min using mobile phases consisting of solvent A: 99.9%
HPLC-grade H2O  0.1% formic acid and solvent B: 99.9%
HPLC-grade CH3CN  0.1% formic acid. Data were collected
using the data-dependent mode. To determine the disulfide
connectivity profiles, the five most intense ions in a high-reso-
lution scan in the Orbitrap were subjected to alternating colli-
sion-induced dissociation and electron transfer dissociation in
the linear ion trap. The resulting data were analyzed using the
Mascot search engine to identify peptides containing free cys-
teine residues, and the disulfide bond patterns were then deter-
mined manually, as described previously (19, 20).
HIV-1 LAI Env-pseudotyped virus mutants
The pRS1 plasmid expressing the full-length LAI molecular
clone (pLAI) was the basis for the WT and mutant viruses used
in these studies (84). Env genes were mutated in the pRS1 plas-
mid using the QuikChange mutagenesis kit (Stratagene) and
cloned into pLAI as SalI–BamHI fragments. The integrity of all
plasmids was verified by sequencing. To create a PG9-sensitive
LAI variant, four substitutions (S162T, G167D, V169K, and
E172V) were introduced into -strand C of the V1V2 domain;
the substitutions were based on the corresponding residues in
the BG505 isolate, which is sensitive to PG9 (42). The outcome
was a 20-fold increase in sensitivity to PG9 neutralization
(IC50  0.1 g/ml compared with 2.0 g/ml for the parental
LAI virus). The resulting LAI-PG9 virus was then used as the
basis for the disulfide mutant viruses described in the results.
Virus evolution cultures
Evolution experiments were performed as described before
(14, 59, 61). A total of 5  106 SupT1 cells were transfected with
5 or 20 g of LAI-PG9. Virus replication in the cultures was
monitored twice a week by visual inspection for the appearance
of syncytia and by using a p24-antigen ELISA. The cultures
were maintained for 3 months, during which period cell-free
supernatants were passaged onto uninfected cells when virus
replication was apparent. Smaller quantities of supernatant were
used for passaging when the extent of virus replication was suffi-
cient to cause significant levels of cell destruction in the cultures.
At regular intervals, cells and filtered supernatant were collected
for storage at 80 °C until needed for genotypic and phenotypic
analyses. When a substantial increase in virus replication was iden-
tified, DNA was extracted from the infected cells using the
QIAamp DNA mini kit (Qiagen). The complete proviral env genes
were PCR-amplified using primers 1 (5	-ATAAGCTTAGCA-
GAAGACAGTGGCAATG-3	) and 2 (5	-GCAAAATCCTTTC-
CAAGCCC-3	) and then sequenced.
Single-round infection assay and neutralization assay
LAI viruses and BG505 Env-pseudotyped viruses were gen-
erated by transfection of 293T cells as described previously (14,
47, 59). Concentration of virus particles in the supernatant was
determined with a p24-antigen ELISA. The TZM-bl reporter
cell line, which stably expresses high levels of CD4 and the co-
receptors CCR5 and CXCR4 and contains the luciferase and
-gal genes under the control of the HIV-1 long-terminal-re-
peat promoter, was obtained through the National Institutes of
Health AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID, National Institutes of Health (John C.
Kappes, Xiaoyun Wu, and Tranzyme Inc., Durham, NC). To
determine infectivity of LAI-PG9 WT and mutant viruses as
well as virus evolution supernatant, a fixed amount of virus (1
ng of CA-p24-antigen equivalent) was tested on the TZM-bl
reporter cell line as described previously (47, 85). To determine
neutralization capacity of monoclonal antibodies, a fixed
amount of BG505 Env-pseudotyped virus (1 ng of CA-p24-an-
tigen equivalent) was incubated for 30 min at room tempera-
ture with 3-fold serial dilutions of the antibody. All infection
and neutralization assays were performed in duplicate. Unin-
fected cells were used to correct for background luciferase
activity. The infectivity of each virus in the absence of antibody
was set at 100%. Nonlinear regression curves were determined,
and the 50% inhibitory concentration (IC50) was calculated
using a sigmoid function in Prism software version 5.0.
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